Free Trial

Calidi Biotherapeutics (CLDI) Competitors

Calidi Biotherapeutics logo
$5.04 -0.82 (-13.99%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$5.30 +0.26 (+5.24%)
As of 08/14/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CLDI vs. MLYS, ZYME, LENZ, TRVI, NRIX, XERS, PHAR, ORIC, DNA, and UPB

Should you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include Mineralys Therapeutics (MLYS), Zymeworks (ZYME), LENZ Therapeutics (LENZ), Trevi Therapeutics (TRVI), Nurix Therapeutics (NRIX), Xeris Biopharma (XERS), Pharming Group (PHAR), Oric Pharmaceuticals (ORIC), Ginkgo Bioworks (DNA), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry.

Calidi Biotherapeutics vs. Its Competitors

Calidi Biotherapeutics (NYSE:CLDI) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 6.7% of Calidi Biotherapeutics shares are owned by insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Calidi Biotherapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.29, suggesting that its share price is 129% less volatile than the S&P 500.

In the previous week, Mineralys Therapeutics had 7 more articles in the media than Calidi Biotherapeutics. MarketBeat recorded 10 mentions for Mineralys Therapeutics and 3 mentions for Calidi Biotherapeutics. Mineralys Therapeutics' average media sentiment score of 0.84 beat Calidi Biotherapeutics' score of 0.50 indicating that Mineralys Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Calidi Biotherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mineralys Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Mineralys Therapeutics has a consensus price target of $32.25, suggesting a potential upside of 128.24%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Calidi Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Calidi Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Mineralys Therapeutics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Calidi Biotherapeutics' return on equity of 0.00% beat Mineralys Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Calidi BiotherapeuticsN/A N/A -344.45%
Mineralys Therapeutics N/A -70.44%-65.51%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calidi BiotherapeuticsN/AN/A-$29.22MN/AN/A
Mineralys TherapeuticsN/AN/A-$177.81M-$3.73-3.79

Summary

Mineralys Therapeutics beats Calidi Biotherapeutics on 8 of the 11 factors compared between the two stocks.

Get Calidi Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLDI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLDI vs. The Competition

MetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$15.25M$282.85M$5.61B$21.04B
Dividend YieldN/AN/A4.61%3.56%
P/E RatioN/AN/A30.2928.01
Price / SalesN/A570.35463.4157.05
Price / CashN/A22.4438.2123.95
Price / Book-2.179.418.825.26
Net Income-$29.22M-$115.81M$3.25B$994.11M
7 Day Performance0.60%2.63%3.70%2.09%
1 Month Performance-26.57%-0.34%5.84%2.35%
1 Year Performance-73.58%-2.92%29.92%13.36%

Calidi Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLDI
Calidi Biotherapeutics
0.7747 of 5 stars
$5.04
-14.0%
N/A-73.4%$15.25MN/A0.0038Short Interest ↓
MLYS
Mineralys Therapeutics
3.1881 of 5 stars
$13.46
+0.4%
$32.25
+139.6%
+54.8%$874MN/A0.0028News Coverage
Earnings Report
Analyst Forecast
Insider Trade
ZYME
Zymeworks
0.2404 of 5 stars
$12.41
-1.0%
N/AN/A$873.83M$76.30M0.00460Earnings Report
LENZ
LENZ Therapeutics
1.1227 of 5 stars
$30.17
-1.0%
$49.60
+64.4%
+74.1%$869.35MN/A0.00110
TRVI
Trevi Therapeutics
3.0722 of 5 stars
$7.27
-1.9%
$20.88
+187.1%
+187.0%$869.14MN/A0.0020
NRIX
Nurix Therapeutics
2.5724 of 5 stars
$10.46
-7.5%
$28.87
+176.0%
-51.8%$864.64M$54.55M0.00300
XERS
Xeris Biopharma
3.4033 of 5 stars
$5.49
+0.2%
$6.25
+13.8%
+186.3%$856.99M$203.07M0.00290News Coverage
Earnings Report
Analyst Upgrade
Insider Trade
Analyst Revision
PHAR
Pharming Group
2.256 of 5 stars
$12.29
-1.5%
$30.00
+144.1%
+45.7%$855.06M$297.20M0.00280Short Interest ↑
High Trading Volume
ORIC
Oric Pharmaceuticals
4.7387 of 5 stars
$9.88
-1.1%
$18.57
+88.0%
+0.6%$851.39MN/A0.0080News Coverage
Earnings Report
Analyst Forecast
Short Interest ↓
DNA
Ginkgo Bioworks
0.9941 of 5 stars
$13.95
-2.3%
$8.50
-39.1%
N/A$835.84M$227.04M0.00640Earnings Report
Gap Down
UPB
Upstream Bio
1.8759 of 5 stars
$16.72
+7.9%
$56.50
+237.9%
N/A$833.80M$2.37M0.0038

Related Companies and Tools


This page (NYSE:CLDI) was last updated on 8/15/2025 by MarketBeat.com Staff
From Our Partners